Psychosis in Parkinson's Disease

被引：1

作者：

Remz, Matthew ^{[1
]}

Salinas, Meagen ^{[1
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75390 USA

来源：

PSYCHIATRIC ANNALS | 2020年 / 50卷 / 03期

关键词：

DRUG-INDUCED PSYCHOSIS; VISUAL HALLUCINATIONS; RISPERIDONE TREATMENT; CLOZAPINE; SYMPTOMS; ZIPRASIDONE; OLANZAPINE; PHENOMENOLOGY; ARIPIPRAZOLE; RIVASTIGMINE;

D O I：

10.3928/00485713-20200210-02

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Clinically defined by consensus in 2007, Parkinson's disease psychosis (PDP) encompasses psychiatric symptoms of illusions, hallucinations, and delusions associated with Parkinson's disease. Since that time, an increase in research has yielded new insights into clinical features of PDP, how these symptoms evolve over time, and novel therapeutic targets. This article reviews the literature surrounding PDP, highlighting the spectrum of clinical manifestations, the pathophysiology, and treatment options. The article concludes with a treatment strategy incorporating the reviewed evidence.

引用

页码：112 / 119

页数：8

共 50 条

[31] Treatment of Parkinson’s Disease Psychosis [J].

Borek L.L. ;

Friedman J.H. .

Current Treatment Options in Psychiatry, 2019, 6 (4) :412-421

[32] Epidemiology of psychosis in Parkinson's disease [J].

Fenelon, Gilles ;

Alves, Guido .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 289 (1-2) :12-17

[33] Psychosis and depression in Parkinson's disease [J].

Brandstädter, D ;

Oertel, WH .

PARKINSON'S DISEASE, 2002, 1 :29-38

[34] Clinical and cognitive features associated with psychosis in Parkinson's disease: a longitudinal study [J].

Flanigan, Joseph L. ;

Harrison, Madaline B. ;

Patrie, James T. ;

Shah, Binit B. ;

Sperling, Scott A. ;

Wyman-Chick, Kathryn A. ;

Dalrymple, William Alex ;

Barrett, Matthew J. .

FRONTIERS IN AGING NEUROSCIENCE, 2024, 16

[35] An update expert opinion on management and research strategies in Parkinson's disease psychosis [J].

Goldman, Jennifer G. ;

Vaughan, Christina L. ;

Goetz, Christopher G. .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (13) :2009-2024

[36] The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease [J].

Divac, Nevena ;

Stojanovic, Radan ;

Vujovic, Katarina Savic ;

Medic, Branislava ;

Damjanovic, Aleksandar ;

Prostran, Milica .

BEHAVIOURAL NEUROLOGY, 2016, 2016

[37] Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders: A Systematic Review [J].

Desmarais, Philippe ;

Massoud, Fadi ;

Filion, Josee ;

Quoc Dinh Nguyen ;

Bajsarowicz, Paulina .

JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2016, 29 (04) :227-236

[38] Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus [J].

Black, Kevin J. ;

Nasrallah, Henry ;

Isaacson, Stuart ;

Stacy, Mark ;

Pahwa, Rajesh ;

Adler, Charles H. ;

Alva, Gustavo ;

Cooney, Jeffrey W. ;

Kremens, Daniel ;

Menza, Matthew A. ;

Meyer, Jonathan M. ;

Patkar, Ashwin A. ;

Simuni, Tanya ;

Morrissette, Debbi A. ;

Stahl, Stephen M. .

CNS SPECTRUMS, 2018, 23 (06) :402-413

[39] Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis [J].

Srisurapanont, Manit ;

Suradom, Chawisa ;

Suttajit, Sirijit ;

Kongsaengdao, Subsai ;

Maneeton, Benchalak .

GENERAL HOSPITAL PSYCHIATRY, 2024, 87 :124-133

[40] Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin [J].

Lyons, Kelly E. ;

Pahwa, Rajesh ;

Hermanowicz, Neal ;

Davis, Thomas ;

Pagan, Fernando ;

Isaacson, Stuart .

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (07) :681-691

← 1 2 3 4 5 →